Autres langues BioMarin Pharmaceutical Inc.

Actions

BMRN

US09061G1013

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 06/05/2024			Varia. 5j.	Varia. 1 janv.
82,1 ^USD	-0,41 %		-0,04 %	-14,85 %

06/05	Un initié de Biomarin Pharmaceutical a vendu des actions d'une valeur de 414 550 $, selon un récent dépôt auprès de la SEC	MT
04/05	Biomarin Pharmaceutical Inc. annonce de nouvelles données positives confirmant la sécurité et l'efficacité de VOXZOGO® (Vosoritide) chez l'enfant	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Biomarin Pharmaceutical Insider Sold Shares Worth $414,550, According to a Recent SEC Filing	06/05
New Data for BioMarin's VOXZOGO for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society Annual Meeting	06/05
Biomarin Pharmaceutical Inc. Announces Positive New Data Supporting the Safety and Efficacy of VOXZOGO® in Children	04/05
BioMarin Pharmaceutical Inc. Announces That Positive New Data Supporting the Safety and Efficacy of VOXZOGO® in Children	04/05
RACCOMANDAZIONI DEGLI ANALISTI USA/UK : Alphabet, Amgen, Starbucks, PayPal, Moderna...	03/05
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Alphabet, Amgen, Starbucks, PayPal, Moderna...	03/05
ANALYST RECOMMENDATIONS : Alphabet, Amgen, Starbucks, PayPal, Moderna...	03/05
BioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS Says	29/04
BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Increase -- Shares Down After Hours	24/04
BioMarin: Q1 Earnings Snapshot	24/04
(BMRN) BIOMARIN PHARMACEUTICAL Forecasts Fiscal Year 2024 EPS Range $2.75 - $2.95	24/04
Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 Revenue $648.8M	24/04
Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 EPS $0.71	24/04
BioMarin Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	24/04
BioMarin Reports Record Financial Results for the First Quarter 2024	24/04
Biomarin Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024	24/04
BioMarin Pharmaceutical : IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE - Form 8-K	23/04
BioMarin Pharmaceutical Investors to Focus Q1 on Strategic Review, Cost-Cutting Measures, UBS Says	22/04
Biomarin Pharmaceutical Insider Sold Shares Worth $3,645,000, According to a Recent SEC Filing	15/04
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET	10/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues BioMarin Pharmaceutical Inc.

Actions

BMRN

US09061G1013

Autres langues

Filtres